港股異動 | 奧園健康高開9.91% 擬2.48億元收購新三板上市公司樂生活80%股份
格隆匯4月23日丨奧園健康(3662.HK)高開9.91%,報7.65港元,暫成交814萬港元,最新總市值55.6億港元。奧園健康昨日盤後宣佈,於2020年4月22日,公司全資附屬奧園健康生活(廣州)集團與京漢控股及田漢訂立框架協議,擬以人民幣2.48億元收購樂生活智慧社區服務集團股份有限公司(其股份於全國中小企業股份轉讓系統掛牌(股份代號:837249)80%股份。公告稱,作為其業務策略的一部分,集團擬透過戰略收購物業管理服務供應商擴大其物業管理服務組合,此舉將令集團獲得進軍新區域市場的途徑及以高效的方式擴大業務組合,因此為實現集團業務策略的有效途徑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.